[1]王凤玲,杨育才,李谦,等.候选药物TW918对K-Ras突变型人肺腺癌A549细胞的体外抑制作用[J].华侨大学学报(自然科学版),2015,36(5):552-557.[doi:10.11830/ISSN.1000-5013.2015.05.0552]
　WANG Feng-ling,YANG Yu-cai,LI Qian,et al.In Vitro Inhibition Effects a Candidate Drug TW918 on K-Ras Mutatant Human Lung Adenocarcinoma Cell Line A549[J].Journal of Huaqiao University(Natural Science),2015,36(5):552-557.[doi:10.11830/ISSN.1000-5013.2015.05.0552]
点击复制

候选药物TW918对K-Ras突变型人肺腺癌A549细胞的体外抑制作用()
分享到：

《华侨大学学报（自然科学版）》[ISSN:1000-5013/CN:35-1079/N]

卷:
第36卷
期数:
2015年第5期
页码:
552-557
栏目:
出版日期:
2015-09-20

文章信息/Info

Title:
In Vitro Inhibition Effects a Candidate Drug TW918 on K-Ras Mutatant Human Lung Adenocarcinoma Cell Line A549
文章编号:
1000-5013(2015)05-0552-06
作者:
王凤玲1;  杨育才2;  李谦1;  王立强1
1. 华侨大学 生物医学学院, 福建 泉州 362021;2. 台湾大学 生化科学系, 台湾 台北 106170
Author(s):
WANG Feng-ling1;  YANG Yu-cai2;  LI Qian1;  WANG Li-qiang1
1. School of Biomedical Sciences, Huaqiao University, Quanzhou 362021, China; 2. Department of Biochemical and Technology, National Taiwan University, Taibei 106170, China
关键词:
K-Ras突变;  肺腺癌;  吉非替尼;  表皮生长因子受体;  PI3K/AKT/mTOR;  信号通路
Keywords:
K-Ras mutations;  lung adenocarcinoma;  gefitinib;  epidermal growth factor;  PI3K/AKT/mTOR;  signal pathway
分类号:
R963
DOI:
10.11830/ISSN.1000-5013.2015.05.0552
文献标志码:
A
摘要:
探讨候选药物TW918对K-Ras突变型人肺腺癌A549细胞的体外抑制作用.以MTT法检测TW918对A549细胞的增殖抑制作用;流式细胞术检测A549细胞周期和凋亡的变化;Western blotting 检测相关蛋白的表达.结果表明:候选药物TW918可以以时间和剂量依赖性地抑制A549细胞的增殖,且作用72 h时抑制效果比吉非替尼高9.93倍;引起细胞周期阻滞于G1期,并诱导细胞发生凋亡;降低A549细胞中p-EGFR的表达,并抑制其下游PI3K/AKT/mTOR信号通路的激活.TW918对K-Ra
Abstract:
This paper is to report the study of the in vitro inhibition effects of a candidate drug TW918 on human lung adenocarcinoma cell line A549, which is heterozygous for the K-Ras mutations. Antiproliferative effects on A549 cells was assessed by MTT assay. Cell cycle distribution and apoptosis were detected by flow cytometer. The protein expression was measured by Western blotting. TW918 showed a strong inhibition of A549 cells proliferation in a time and concentration dependent manner, 9.93 times higher than gefitinib after 72 h. TW918 could induce cell cycle arrested at G1 phase and apoptosis. TW918 also inhibited the expression of p-EGFR and the activation of PI3K/AKT/mTOR signal pathway in A549 cells. In conclusion, TW918 has the antitumor effects on gefitinib resistant cell line A549, bearing the K-Ras mutations, through inhibiting EGFR and PI3K/AKT/mTOR signal pathway.

参考文献/References:

[1] PAO W,MILLER V A,POLITI K A,et al.Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain[J].PLOS Med,2005,2(3):e73.
[2] 章九云,韩静,张勇,等.4-取代-7-氯喹啉衍生物的合成及抗肿瘤活性的初步评价[J].中国新药杂志,2014,23(5):88-94.
[3] DONG Song,ZHANG Xu-chao,CHENG Hua,et al.Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors[J].Cancer Chemoth Pharm,2012,70(5):707-716.
[4] LA M S,GALETTI M,ALFIERI R R,et al.Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines[J].Biochem Pharmaco,2009,78(5):460-468.
[5] MUKOHARA T,ENGELMAN J A,HANNA N H,et al.Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearingepidermal growth factor receptor mutations[J].J Natl Cancer Inst,2005,97(16): 1185-1194.
[6] HYNES N E,LANE H A.ERBB receptors and cancer: The complexity of targeted inhibitors[J].Nat Rev Cancer,2005,5(5):341-354.
[7] RECK M,van ZANDWIJK N,GRIDELLI C,et al.Erlotinib in advancednon-small cell lung cancer: Efficacy and safety findings of the global phase Ⅳ tarceva lung cancer survival treatment study[J].J Thorac Oncol,2010,5(10):1616-1622.
[8] PEDERSEN M W,PEDERSEN N,OTTESEN L H,et al.Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII[J].Br J Cancer,2005,93(8):915-923.
[9] TISEO M,ROSSI G,CAPELLETTI M,et al.Predictors of gefitinib outcomes in advanced non-small cell lung cancer(NSCLC): Study of a comprehensive panel of molecular markers[J].Lung Cancer,2010,67(3):355-360.
[10] DANCEY J E.Agents targeting ras signaling pathway[J].Curr Pharm Des,2002,8(25):2259-2267.

备注/Memo

备注/Memo:
收稿日期: 2014-07-06
通信作者: 王立强(1970-),男,教授,博士,主要从事药剂学和新药开发的研究.E-mail:wlq1599@163.com.
基金项目: 福建省自然科学基金资助项目(2010J01208); 福建省泉州市科技计划重点项目(2013Z35)
更新日期/Last Update: 2015-09-20